Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 718-720

  Advani, Ranjana H ^a   Hong, Fangxin ^b   Horning, Sandra J ^a,c   Kahl, Brad S ^d   Manola, Judith ^b   Swinnen, Lode J ^e   Habermann, Thomas M ^f   Ganjoo, Kristen ^a  

^a STANFORD UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MAYO CLINIC   (United States)

Author keywords

Avastin; Cardiac; PTCL

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; AGED; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; HEART ARRHYTHMIA; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; LETTER; MAINTENANCE THERAPY; MONITORING; MULTIPLE CYCLE TREATMENT; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PREDNISOLONE; VINCRISTINE;

EID: 84859097240     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.623256     Document Type: Letter

References (15)

1. Savage KJ. Aggressive peripheral T-cell lymphomas (specifi ed and unspecifi ed types). Hematology Am Soc Hematol Educ Program 2005; 267-277. 10.1182/asheducation-2005.1.267.
2. Jorgensen JM, Sorensen FB, Bendix K, et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic signifi cance in specifi c subtypes. Leuk Lymphoma 2007; 48:584-595.
3. Paydas S, Seydaoglu G, Ergin M, et al. Th e prognostic signifi cance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leuk Lymphoma 2009;50:366-373.
4. de Leval L, Rickman DS, Th ielen C, et al. Th e gene expression profi le of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007;109: 4952-4963.
5. Habermann TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diff use large B-cell lymphoma. J Clin Oncol 2006;24: 3121-3127.
6. D 'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-7142.
7. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011;29:632-638.
8. Miller KD, O'Neill A, Perez EA, et al. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol 2008;26:520a.
9. Ganjoo KN, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diff use large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006;47:998-1005.
10. Stopeck AT, Unger JM, Rimsza LM, et al. Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diff use Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515. Blood 2010;116:591a.
11. Verma N, Swain SM. Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? J Clin Oncol 2011;29: 603-606.
12. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280:C1375-C1386.
13. Pereg D, Lishner M. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? Eur Heart J 2008; 29:2325-2326.
14. Giordano FJ, Gerber HP, Williams SP, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 2001;98:5780-5785.
15. Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010;23:460-468.